Reata Pharmaceuticals, Inc. (RETA)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
79.07+0.72 (+0.92%)
At close: 4:00PM EDT
79.07 0.00 (0.00%)
After hours: 4:41PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 78.35 |
| Open | 78.42 |
| Bid | 78.72 x 800 |
| Ask | 84.99 x 900 |
| Day's Range | 77.25 - 80.50 |
| 52 Week Range | 77.25 - 186.82 |
| Volume | 237,734 |
| Avg. Volume | 294,111 |
| Market Cap | 2.868B |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.35 |
| Earnings Date | May 06, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 232.67 |
- Zacks
Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss
Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.
- Motley Fool
Reata Pharmaceuticals, Inc. (RETA) Q1 2021 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Reata Pharmaceuticals' First Quarter 2021 Financial Results and Update on Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call today on Reata's website at reatapharma.com in the Investors section.
- Zacks
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 14.68% and -32.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
© 2021 Verizon Media. All rights reserved.
